Ligands of Immunopharmacology

[8]-Shogaol, one of the pungent phenolic compounds in ginger, exhibits anti-platelet activity ( IC 50 =5 μM) and inhibits COX-2 ( IC 50 =17.5 μM). [8]-Shogaol induces apoptosis in human leukemia cells.Form:Liquid

[8]-Shogaol, one of the pungent phenolic compounds in ginger, exhibits anti-platelet activity ( IC 50 =5 μM) and inhibits COX-2 ( IC 50 =17.5 μM). [8]-Shogaol induces apoptosis in human leukemia cells.Form:Liquid

[8]-Shogaol, one of the pungent phenolic compounds in ginger, exhibits anti-platelet activity ( IC 50 =5 μM) and inhibits COX-2 ( IC 50 =17.5 μM). [8]-Shogaol induces apoptosis in human leukemia cells.

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial

Ac-Gly-BoroPro is a selective FAP inhibitor with a K i of 23 nM.In VitroFAP has been implicated in cancer however, its specific role remains elusive because inhibitors that distinguish FAP from other prolyl peptidases like dipeptidyl peptidase-4

Ac-Gly-BoroPro is a selective FAP inhibitor with a K i of 23 nM.In VitroFAP has been implicated in cancer however, its specific role remains elusive because inhibitors that distinguish FAP from other prolyl peptidases like dipeptidyl peptidase-4